Diabetic Neuropathy Classification and Management

Pathophysiology and Clinical Characteristics

The pain experienced in diabetic neuropathy is classified as neuropathic pain, defined as "pain arising as a direct consequence of abnormalities in the somatosensory system in people with diabetes," according to the American Diabetes Association 1
Neuropathic pain in diabetes results from direct nerve damage through both peripheral and central mechanisms, including changes in sodium and calcium channel distribution and expression, altered neuropeptide expression, peripheral sensitization, damage to small nerve fibers, axonal atrophy, degeneration, or regeneration, central sensitization, Aβ fiber sprouting into lamina II of the dorsal horn, and reduced inhibition via descending pathways 2, 3
Patients describe characteristic neuropathic pain symptoms including burning pain, "electrical shock" sensations, stabbing or knife-like pains, uncomfortable tingling, and allodynia (pain from normally non-painful stimuli like clothing), which are pathognomonic for neuropathic rather than somatic pain 1, 4

Recognizing diabetic neuropathy as neuropathic pain is critical because it directs appropriate pharmacological management, with first-line treatments including pregabalin, duloxetine, and gabapentin, all specifically indicated for neuropathic pain, as recommended by the American Academy of Neurology 1, 6
Alternative options include tricyclic antidepressants, venlafaxine, and carbamazepine, and topical agents like capsaicin are used as adjuvants 6, 1
These medications target the aberrant neural signaling mechanisms of neuropathic pain, not inflammatory mediators (as in somatic pain) or vascular insufficiency (as in ischemic pain), with a strength of evidence level of high for the use of pregabalin and duloxetine 1, 4